Acknowledgements
Cancer
CANCER
We thank the 60 patients who participated in the trial and their families, the ALTER-004 investigators at the 5 clinical sites and their teams, Tianjin Medical University Cancer Institute & Hospital, Tianjin Medical University General Hospital, Affiliated Hospital of Hebei University, First Hospital of Shijiazhuang and Inner Mongolia Autonomous Region People’s Hospital.